Evidence map›Paper›PMID 29084565›Full record

ArticleMolecular neurodegeneration2017

Haplotype-specific MAPT exon 3 expression regulated by common intronic polymorphisms associated with Parkinsonian disorders.

Mang Ching Lai, Anne-Laure Bechy, Franziska Denk, Emma Collins, Maria Gavriliouk, Judith B Zaugg, Brent J Ryan, Richard Wade-Martins, Tara M Caffrey

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?Antioxidants (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mang Ching LaiDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Anne-Laure BechyDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Franziska DenkDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Emma CollinsDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Maria GavrilioukDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Judith B ZauggEuropean Molecular Biology Laboratory, 69117, Heidelberg, Germany.
Brent J RyanDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
Richard Wade-MartinsDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK. richard.wade-martins@dpag.ox.ac.uk.
Tara M CaffreyDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK. tara.caffrey@dpag.ox.ac.uk.
University of Oxford · GBEuropean Molecular Biology Laboratory · DE

Funding

Medical Research Council MR/L022656/1Parkinson's UK H-1102Parkinson's UK J-0901
6 · The paper itself

Abstract

backgroundGenome wide association studies have identified microtubule associated protein tau (MAPT) H1 haplotype single nucleotide polymorphisms (SNPs) as leading common risk variants for Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration. The MAPT risk variants fall within a large 1.8 Mb region of high linkage disequilibrium, making it difficult to discern the functionally important risk variants. Here, we leverage the strong haplotype-specific expression of MAPT exon 3 to investigate the functionality of SNPs that fall within this H1 haplotype region of linkage disequilibrium.

methodsIn this study, we dissect the molecular mechanisms by which haplotype-specific SNPs confer allele-specific effects on the alternative splicing of MAPT exon 3. Firstly, we use haplotype-hybrid whole-locus genomic MAPT vectors studies to identify functional SNPs. Next, we characterise the RNA-protein interactions at two loci by mass spectrometry. Lastly, we knockdown candidate splice factors to determine their effect on MAPT exon 3 using a novel allele-specific qPCR assay.

resultsUsing whole-locus genomic DNA expression vectors to express MAPT haplotype variants, we demonstrate that rs17651213 regulates exon 3 inclusion in a haplotype-specific manner. We further investigated the functionality of this region using RNA-electrophoretic mobility shift assays to show differential RNA-protein complex formation at the H1 and H2 sequence variants of SNP rs17651213 and rs1800547 and subsequently identified candidate trans-acting splicing factors interacting with these functional SNPs sequences by RNA-protein pull-down experiment and mass spectrometry. Finally, gene knockdown of candidate splice factors identified by mass spectrometry demonstrate a role for hnRNP F and hnRNP Q in the haplotype-specific regulation of exon 3 inclusion.

conclusionsWe identified common splice factors hnRNP F and hnRNP Q regulating the haplotype-specific splicing of MAPT exon 3 through intronic variants rs1800547 and rs17651213. This work demonstrates an integrated approach to characterise the functionality of risk variants in large regions of linkage disequilibrium.

Indexed as

Alternative SplicingExonsGenetic Predisposition to DiseaseHaplotypesHumansLinkage DisequilibriumParkinsonian DisordersPolymorphism, Single NucleotideProtein Isoformstau ProteinsMAPT protein, humanProtein Isoformstau ProteinsAlzheimer’s diseaseCorticobasal degenerationMAPTParkinson’s diseaseProgressive supranuclear palsyTau

Identifiers

PMID29084565
PMCPMC5663040
OpenAlexW2765801163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.